Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

5,606 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A multicenter phase I/II study of enzalutamide in Japanese patients with castration-resistant prostate cancer.
Akaza H, Uemura H, Tsukamoto T, Ozono S, Ogawa O, Sakai H, Oya M, Namiki M, Fukasawa S, Yamaguchi A, Uemura H, Ohashi Y, Maeda H, Saito A, Takeda K, Naito S. Akaza H, et al. Among authors: takeda k. Int J Clin Oncol. 2016 Aug;21(4):773-782. doi: 10.1007/s10147-016-0952-6. Epub 2016 Jan 21. Int J Clin Oncol. 2016. PMID: 26793974 Free PMC article. Clinical Trial.
The efficacy and safety of degarelix, a GnRH antagonist: a 12-month, multicentre, randomized, maintenance dose-finding phase II study in Japanese patients with prostate cancer.
Ozono S, Ueda T, Hoshi S, Yamaguchi A, Maeda H, Fukuyama Y, Takeda K, Ohashi Y, Tsukamoto T, Naito S, Akaza H. Ozono S, et al. Among authors: takeda k. Jpn J Clin Oncol. 2012 Jun;42(6):477-84. doi: 10.1093/jjco/hys035. Epub 2012 Mar 28. Jpn J Clin Oncol. 2012. PMID: 22457321 Clinical Trial.
Safety and Antitumor Activity of Repeated ASP3026 Administration in Japanese Patients with Solid Tumors: A Phase I Study.
Ono A, Murakami H, Seto T, Shimizu T, Watanabe S, Takeshita S, Takeda K, Toyoshima J, Nagase I, Bahceci E, Morishita M, Morita S, Fukuoka M, Nakagawa K. Ono A, et al. Among authors: takeda k. Drugs R D. 2021 Mar;21(1):65-78. doi: 10.1007/s40268-020-00331-2. Epub 2020 Dec 17. Drugs R D. 2021. PMID: 33331996 Free PMC article. Clinical Trial.
ASP8273 tolerability and antitumor activity in tyrosine kinase inhibitor-naïve Japanese patients with EGFR mutation-positive non-small-cell lung cancer.
Azuma K, Nishio M, Hayashi H, Kiura K, Satouchi M, Sugawara S, Hida T, Iwamoto Y, Inoue A, Takeda K, Ikeda S, Nakagawa T, Takeda K, Asahina S, Komatsu K, Morita S, Fukuoka M, Nakagawa K. Azuma K, et al. Among authors: takeda k. Cancer Sci. 2018 Aug;109(8):2532-2538. doi: 10.1111/cas.13651. Epub 2018 Jun 29. Cancer Sci. 2018. PMID: 29807396 Free PMC article. Clinical Trial.
A phase 1 study of oral ASP5878, a selective small-molecule inhibitor of fibroblast growth factor receptors 1-4, as a single dose and multiple doses in patients with solid malignancies.
Yamamoto N, Ryoo BY, Keam B, Kudo M, Lin CC, Kunieda F, Ball HA, Moran D, Komatsu K, Takeda K, Fukuda M, Furuse J, Morita S, Doi T. Yamamoto N, et al. Among authors: takeda k. Invest New Drugs. 2020 Apr;38(2):445-456. doi: 10.1007/s10637-019-00780-w. Epub 2019 Apr 30. Invest New Drugs. 2020. PMID: 31041575 Clinical Trial.
Clinical activity of ASP8273 in Asian patients with non-small-cell lung cancer with EGFR activating and T790M mutations.
Murakami H, Nokihara H, Hayashi H, Seto T, Park K, Azuma K, Tsai CM, Yang JC, Nishio M, Kim SW, Kiura K, Inoue A, Takeda K, Kang JH, Nakagawa T, Takeda K, Akazawa R, Kaneko Y, Shimazaki M, Morita S, Fukuoka M, Nakagawa K. Murakami H, et al. Among authors: takeda k. Cancer Sci. 2018 Sep;109(9):2852-2862. doi: 10.1111/cas.13724. Epub 2018 Aug 9. Cancer Sci. 2018. PMID: 29972716 Free PMC article. Clinical Trial.
5,606 results